Cannabis-related plants serve as the source of the herbal medicine known as marijuana. Cancer and chronic pain are two conditions for which cannabis is used as a therapeutic component. The market is anticipated to grow at a CAGR of 32.04 percent from 2021 to 2028, reaching $197.74 billion. In the upcoming quarters, US-based businesses are more likely to surpass their Canadian competitors. This is as a result of marijuana being quickly legalized and having a larger market in the US. Less than ten percent (8%) believe marijuana should not be permitted for adult usage. The marijuana market is expected to grow to be a very profitable business option and a great source of growth for your portfolio. Companies like Tilray, Inc. and Jazz Pharmaceuticals Inc. are prepared to profit from these changes.

¬†Insider Monkey chose 10 medical marijuana stocks to buy now. The net income for the first quarter of 2022 for Green Thumb Industries Inc. increased by 179 percent to $28.9 million ($0.12 per basic and diluted share). Seaport Global analyst Sonny Randhawa started coverage of the firm with a Buy rating and a $15 price objective. An American business called Trulieve Cannabis Corp. deals in the sale of medical cannabis goods and services. It grows and produces its goods on-site, then distributes them to stores under its own name and also delivers them home to patients. Located in Delta, British Columbia, Canada, Village Farms International, Inc. is a vertically integrated provider of vegetables and marijuana. Given the anticipated significant near-term growth in Canadian cannabis and the shares’ discount to peers, Craig-Hallum analyst kept a Buy rating on the stock. In its third fiscal quarter of 2022, OrganiGram Holdings Inc. reported substantial revenue growth. Strong Canadian adult-use sales drove the company’s sales over Wall Street projections. The amount of revenue for the quarter was $29.09 million, an increase of 79.14 percent from the same period last year. A corporation specializing in both medicinal marijuana and adult-use recreational cannabis is called Cronos Group Inc. In the second quarter of the company’s fiscal year 2022, medical marijuana sales were $45.7 million, accounting for 75% of total revenue. For more details, click 10 Medical Marijuana Stocks To Buy Now.